These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 25087583)
1. Assessing the impact of patient self-selection on the costs to treat latent tuberculosis infection (LTBI) with isoniazid and transitional rifampin. Fluegge KR J Eval Clin Pract; 2014 Oct; 20(5):685-91. PubMed ID: 25087583 [TBL] [Abstract][Full Text] [Related]
2. Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB. Aspler A; Long R; Trajman A; Dion MJ; Khan K; Schwartzman K; Menzies D Thorax; 2010 Jul; 65(7):582-7. PubMed ID: 20627913 [TBL] [Abstract][Full Text] [Related]
3. Potential cost-effectiveness of rifampin vs. isoniazid for latent tuberculosis: implications for future clinical trials. Esfahani K; Aspler A; Menzies D; Schwartzman K Int J Tuberc Lung Dis; 2011 Oct; 15(10):1340-6. PubMed ID: 22283892 [TBL] [Abstract][Full Text] [Related]
4. A prospective cohort study of latent tuberculosis in adult close contacts of active pulmonary tuberculosis patients in Korea. Park SH; Lee SJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Kim HJ; Menzies D Korean J Intern Med; 2016 May; 31(3):517-24. PubMed ID: 27052266 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of rifampin for 4 months and isoniazid for 6 months in the treatment of tuberculosis infection. Pina JM; Clotet L; Ferrer A; Sala MR; Garrido P; Salleras L; Domínguez A Respir Med; 2013 May; 107(5):768-77. PubMed ID: 23490222 [TBL] [Abstract][Full Text] [Related]
6. Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan. Huang YW; Yang SF; Yeh YP; Tsao TC; Tsao SM Medicine (Baltimore); 2016 Aug; 95(34):e4126. PubMed ID: 27559940 [TBL] [Abstract][Full Text] [Related]
7. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Page KR; Sifakis F; Montes de Oca R; Cronin WA; Doherty MC; Federline L; Bur S; Walsh T; Karney W; Milman J; Baruch N; Adelakun A; Dorman SE Arch Intern Med; 2006 Sep; 166(17):1863-70. PubMed ID: 17000943 [TBL] [Abstract][Full Text] [Related]
8. Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population. Jiménez-Fuentes MA; de Souza-Galvao ML; Mila Augé C; Solsona Peiró J; Altet-Gómez MN Int J Tuberc Lung Dis; 2013 Mar; 17(3):326-32. PubMed ID: 23407221 [TBL] [Abstract][Full Text] [Related]
9. Treatment of latent tuberculosis infection: An update. Lobue P; Menzies D Respirology; 2010 May; 15(4):603-22. PubMed ID: 20409026 [TBL] [Abstract][Full Text] [Related]
11. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Lardizabal A; Passannante M; Kojakali F; Hayden C; Reichman LB Chest; 2006 Dec; 130(6):1712-7. PubMed ID: 17166986 [TBL] [Abstract][Full Text] [Related]
12. Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment. Trajman A; Long R; Zylberberg D; Dion MJ; Al-Otaibi B; Menzies D Int J Tuberc Lung Dis; 2010 May; 14(5):551-9. PubMed ID: 20392347 [TBL] [Abstract][Full Text] [Related]
13. An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study. Surey J; Stagg HR; Yates TA; Lipman M; White PJ; Charlett A; Muñoz L; Gosce L; Rangaka MX; Francis M; Hack V; Kunst H; Abubakar I BMC Infect Dis; 2021 Jan; 21(1):90. PubMed ID: 33478428 [TBL] [Abstract][Full Text] [Related]
14. A comparative effectiveness analysis of treatment for latent tuberculosis infection using multilevel selection models. Fluegge KR; Roe BE J Comp Eff Res; 2015 May; 4(3):239-257. PubMed ID: 25965321 [TBL] [Abstract][Full Text] [Related]
15. Safety and completion of a 4-month course of rifampicin for latent tuberculous infection in children. Cruz AT; Starke JR Int J Tuberc Lung Dis; 2014 Sep; 18(9):1057-61. PubMed ID: 25189552 [TBL] [Abstract][Full Text] [Related]
16. Two-month regimen of isoniazid, rifampin and pirazinamid for latent tuberculosis infection. Duarte R; Carvalho A; Correia A Public Health; 2012 Sep; 126(9):760-2. PubMed ID: 22633080 [No Abstract] [Full Text] [Related]
17. Health System Costs of Treating Latent Tuberculosis Infection With Four Months of Rifampin Versus Nine Months of Isoniazid in Different Settings. Bastos ML; Campbell JR; Oxlade O; Adjobimey M; Trajman A; Ruslami R; Kim HJ; Baah JO; Toelle BG; Long R; Hoeppner V; Elwood K; Al-Jahdali H; Apriani L; Benedetti A; Schwartzman K; Menzies D Ann Intern Med; 2020 Aug; 173(3):169-178. PubMed ID: 32539440 [TBL] [Abstract][Full Text] [Related]